454 related articles for article (PubMed ID: 29328861)
1. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
Rajyaguru DJ; Borgert AJ; Smith AL; Thomes RM; Conway PD; Halfdanarson TR; Truty MJ; Kurup AN; Go RS
J Clin Oncol; 2018 Feb; 36(6):600-608. PubMed ID: 29328861
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare.
Parikh ND; Marshall VD; Green M; Lawrence TS; Razumilava N; Owen D; Singal AG; Feng M
J Med Imaging Radiat Oncol; 2018 Oct; 62(5):673-681. PubMed ID: 29877615
[TBL] [Abstract][Full Text] [Related]
4. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
Wahl DR; Stenmark MH; Tao Y; Pollom EL; Caoili EM; Lawrence TS; Schipper MJ; Feng M
J Clin Oncol; 2016 Feb; 34(5):452-9. PubMed ID: 26628466
[TBL] [Abstract][Full Text] [Related]
5. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
Wang F; Numata K; Takeda A; Ogushi K; Fukuda H; Nihonmatsu H; Hara K; Chuma M; Tsurugai Y; Maeda S
BMC Cancer; 2021 Oct; 21(1):1169. PubMed ID: 34717577
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis.
Sapisochin G; Barry A; Doherty M; Fischer S; Goldaracena N; Rosales R; Russo M; Beecroft R; Ghanekar A; Bhat M; Brierley J; Greig PD; Knox JJ; Dawson LA; Grant DR
J Hepatol; 2017 Jul; 67(1):92-99. PubMed ID: 28257902
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis.
Hara K; Takeda A; Tsurugai Y; Saigusa Y; Sanuki N; Eriguchi T; Maeda S; Tanaka K; Numata K
Hepatology; 2019 Jun; 69(6):2533-2545. PubMed ID: 30805950
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.
Kim N; Kim HJ; Won JY; Kim DY; Han KH; Jung I; Seong J
Radiother Oncol; 2019 Feb; 131():81-87. PubMed ID: 30773192
[TBL] [Abstract][Full Text] [Related]
9. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis.
Seo YS; Kim MS; Yoo HJ; Jang WI; Paik EK; Han CJ; Lee BH
Cancer Med; 2016 Nov; 5(11):3094-3101. PubMed ID: 27709795
[TBL] [Abstract][Full Text] [Related]
10. Radiofrequency ablation versus stereotactic body radiotherapy for hepatocellular carcinoma: a meta-analysis.
Zhang H; Chang N; Han T; Ma S; Qu G; Liu H; Sun C; Cheng C; Zhou Q; Sun Y
Future Oncol; 2021 Oct; 17(30):4027-4040. PubMed ID: 34278818
[TBL] [Abstract][Full Text] [Related]
11. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
12. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile?
Rim CH; Lee HY; Kim JS; Kim H
Int J Radiat Biol; 2021; 97(2):111-119. PubMed ID: 33253598
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma.
Ji R; Ng KK; Chen W; Yang W; Zhu H; Cheung TT; Chiang CL; Wong TCL; Kong FM; Wu G; Lo CM
Medicine (Baltimore); 2022 Jan; 101(4):e28545. PubMed ID: 35089192
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
[TBL] [Abstract][Full Text] [Related]
15. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
[TBL] [Abstract][Full Text] [Related]
16. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis.
Liu W; Zheng Y; He W; Zou R; Qiu J; Shen J; Yang Z; Zhang Y; Wang C; Wang Y; Zuo D; Li B; Yuan Y
Aliment Pharmacol Ther; 2018 Sep; 48(6):671-681. PubMed ID: 30063081
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma.
Endo K; Kuroda H; Oikawa T; Okada Y; Fujiwara Y; Abe T; Sato H; Sawara K; Takikawa Y
Scand J Gastroenterol; 2018 Dec; 53(12):1575-1583. PubMed ID: 30577723
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0-B1 hepatocellular carcinoma.
Wang F; Numata K; Takeda A; Ogushi K; Fukuda H; Hara K; Chuma M; Eriguchi T; Tsurugai Y; Maeda S
PLoS One; 2021; 16(1):e0245076. PubMed ID: 33400718
[TBL] [Abstract][Full Text] [Related]
19. Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation and/or Transcatheter Arterial Chemoembolization: A Propensity Score-Matched Analysis.
Orimo T; Kamiyama T; Yokoo H; Wakayama K; Shimada S; Einama T; Kamachi H; Taketomi A
Dig Surg; 2018; 35(5):427-434. PubMed ID: 28903105
[TBL] [Abstract][Full Text] [Related]
20. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review.
Lee J; Shin IS; Yoon WS; Koom WS; Rim CH
Radiother Oncol; 2020 Apr; 145():63-70. PubMed ID: 31923711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
